Navigation Links
Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
Date:6/30/2009

ssels, inhibiting tumor growth and proliferation. In addition, a growing body of evidence supports the active role of PS in immune signaling, with recent research showing that exposed PS can have an immunosuppressive effect and dampen the body's normal response to cancer. By binding to and blocking PS, bavituximab is believed to boost the body's ability to combat cancer via this second immunostimulatory mechanism. Further information on the role of exposed PS in the tumor environment can be found in the Anti-PS Technical Backgrounder posted at www.peregrineinc.com.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company may not h
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... York, NY (PRWEB) July 11, 2014 ... http://www.gynecaremorcellatorlawsuit.com/ ) investigation, Bernstein Liebhard LLP has been ... Food & Drug Administration’s (FDA) Obstetrics and ... explore ways to mitigate the cancer risks associated ... invasive gynecological surgeries. According to a report published ...
(Date:7/11/2014)... Datalogic brings a new and innovative ... wide. With their new Gryphon GD4400 and ... the devastating MRSA, which claimed 5,500 lives, becomes more ... 2D and the Gryphon GM4400-HC 2D readers can scan ... read barcodes off of troublesome LCD monitors, smartphones, and ...
(Date:7/11/2014)... people with sex addiction, pornography affects the brain in ... addicts as they consume drugs, a new study finds. ... patients who have compulsive sexual behavior and healthy volunteers. ... Dr. Valerie Voon, of the University of Cambridge in ... research involved 19 men with sex addiction and a ...
(Date:7/11/2014)... Ticket Down is a reliable source for ... When it comes to the summer concert schedule, it just isn’t ... is one of the biggest names in country music and one ... out on his “That’s My Kind of Night” tour featuring Lee ... be making through the rest of the summer and into the ...
(Date:7/11/2014)... According to a new market research ... Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, RFID), Application ... Transportation, Agriculture) & Geography - Global Trends & Forecasts ... Things market was worth $1029.5 Billion in 2013, and ... an estimated CAGR of 4.08% from 2014 to 2020. ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4
... 50% of fertility clinics in the US are allowing parents ... It also found that in 9 percent of the cases ... ,Dr. William Gibbons, president of the Society for Assisted ... most cases the gender selection tests were being performed for ...
... Refugees residing on temporary protection visas (TPVs) are ... mental health problems than those with permanent protection ... psychiatrists have revealed. ,Anxiety, post-traumatic stress ... for TPV holders than for PPV holders, mental ...
... steady partners, according to a new study. One in 10 men ... admitted that it was a regular habit. // ,"Approximately ... relationship," said Dr Tamsin Groom, of the Sandyford Initiative in Glasgow. ... used condoms in most cases except when they were out of ...
... vaccines to prevent severe gastroenteritis should now be made ... the latest issue of the Medical Journal of Australia. ... having such an effective tool to prevent a common, ... and Ruth Bishop say in an editorial. ...
... kills hundreds of thousands worldwide, infect by stealth. ... the very immune system// cells the body relies ... ,Just how Salmonella escapes detection by macrophages, ... infection, has seemed impossibly complicated, a needle-in-a-haystack proposition ...
... The U.S. physician workforce has released a study saying ... aging US population. Researchers from the University// of Utah ... said that the health needs of the population were ... report, titled "Family Physician Workforce Reform: Recommendations of the ...
Cached Medicine News:Health News:Detention, Uncertainty take their Toll on the Mental Health of Refugees 2Health News:Experts Call for Rotavirus Vaccine for All 2Health News:An Infectious Agent of Deception, Exposed Through Proteomics 2Health News:Call To Increase Family Physicians 2Health News:Call To Increase Family Physicians 3
(Date:7/10/2014)... Virginia , 11. Juli 2014 ... von Kameras für die molekulare Bildgebung, ... hat heute die CE-Zulassung für sein ... CE-Zeichen kann Dilon das Produkt jetzt ... auf den Großteil der europäischen Länder ...
(Date:7/10/2014)... , July 10, 2014  RESMED INC. (NYSE: ... fourth quarter and fiscal year ended June 30, 2014 results ... Exchange market close. A press release with ResMed,s results will ... company will host a webcast to discuss operating results and ... begin at 1:30 p.m. US Pacific Time and the live ...
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Fenwick & West, a leading technology and life sciences ... joined the firm as a partner in its Life Sciences ... clients as a strategic counselor on a broad range of ... and secretary at AVI BioPharma, Ms. Toshav is based in ...
... 14, 2012 Medical device recalls increased more than ... more than five times as many units than the ... released today. Products impacted by the increase ... Consumer product recalls also increased in the first quarter ...
Cached Medicine Technology:Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform 2Medical Device Recalls Soar During First Quarter, ExpertRECALL Index Shows 2Medical Device Recalls Soar During First Quarter, ExpertRECALL Index Shows 3
... Flash Cards is designed ... heart, veins, and arteries ... It uses the time ... from BryanEdwards.com and displays ...
... Consult is the perfect quick consult ... diagnosis and management of both common ... of chest pain to the management ... quick reference makes the most of ...
... Unbound Surgery, published by ... innovative digital resource that ... and leading edge technology. ... that is specifically engineered ...
... guide to the management of ... offers a response from leading ... the more common, and often ... cardiology. It is a "how-to" ...
Medicine Products: